Functional Genomics for Cell-Therapy Matching: Enhancing Precision in Regenerative Medicine

Abstract

Functional genomics has revolutionized the landscape of personalized medicine, particularly in the realm of cell therapy. By integrating high-throughput genomic data with functional biological insights, clinicians and researchers are increasingly able to optimize cell-therapy matching, improving efficacy and minimizing adverse outcomes. This review synthesizes current evidence, explores the underlying mechanisms, discusses clinical applications, and examines future directions in the use of functional genomics for cell-therapy matching, offering a comprehensive resource for healthcare professionals engaged in regenerative medicine.

Introduction

Cell therapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptor T-cell (CAR-T) therapy, and emerging allogeneic and autologous cell-based treatments, has become a cornerstone in managing various malignancies, immunological, and degenerative diseases. However, heterogeneity in patient response and risks such as graft-versus-host disease (GVHD), relapse, or therapy resistance highlight the need for more precise donor-recipient matching. Functional genomics, which combines genomic sequencing with transcriptomics, proteomics, and epigenomics, provides a multidimensional perspective on cellular function and compatibility. This article reviews the clinical and scientific basis of functional genomics for cell-therapy matching, emphasizing its impact on patient outcomes.

Epidemiology / Disease Burden

The global burden of diseases amenable to cell therapy, including hematologic malignancies, inherited immunodeficiencies, and autoimmune disorders, remains substantial. Annually, tens of thousands of patients undergo HSCT worldwide, while CAR-T and mesenchymal stem cell therapies are rapidly expanding. Despite advancements, treatment failure, complications, and donor scarcity persist, necessitating improved matching strategies. Epidemiological studies suggest that mismatched or suboptimally matched cell therapies contribute significantly to morbidity, mortality, and healthcare costs, underscoring the clinical imperative for precision approaches.

Pathophysiology

Successful cell therapy relies on intricate immunogenetic interactions between donor and recipient. Key determinants include human leukocyte antigen (HLA) compatibility, minor histocompatibility antigens, and non-HLA genomic variants influencing immune recognition, engraftment, and therapeutic function. Functional genomics deciphers these complexities by mapping gene expression profiles, regulatory networks, and epigenetic landscapes that govern immune cell behavior, cytokine signaling, and susceptibility to complications such as GVHD or cytokine release syndrome (CRS). Mechanism-based insights from functional genomics enable identification of recipient-specific vulnerabilities and donor cell attributes that predict therapeutic success or failure.

Risk Factors

Traditional risk factors for poor cell therapy outcomes include HLA mismatch, donor-recipient age disparity, underlying disease status, and comorbidities. Functional genomic profiling has expanded this paradigm to include genetic polymorphisms in immune-regulatory genes (e.g., KIR, NKG2D ligands), transcriptional signatures of immune exhaustion, and epigenetic markers of cellular senescence. These novel risk factors are increasingly being incorporated into risk stratification models, enabling more nuanced selection and optimization of donor cells and recipients for cell therapy.

Clinical Features

Clinical manifestations of suboptimal cell-therapy matching range from acute complications such as GVHD, CRS, and infection, to chronic issues like relapse, poor engraftment, and long-term immunodeficiency. Functional genomics provides predictive biomarkers—such as gene expression profiles associated with T-cell alloreactivity or regulatory T-cell abundance—that correlate with clinical features and can guide pre-emptive management strategies. Integration of these features into clinical workflows enhances the ability to anticipate and mitigate adverse events.

Diagnosis

Diagnostic approaches now extend beyond HLA typing to encompass comprehensive genomic and functional assessments. Next-generation sequencing (NGS) enables high-resolution HLA typing, minor antigen genotyping, and detection of actionable somatic mutations. Transcriptomic and proteomic analyses of donor and recipient immune cells yield functional readouts, informing compatibility and therapeutic potential. Flow cytometry, single-cell RNA sequencing, and CRISPR-based functional screens are increasingly used to validate genomic findings and tailor cell-therapy protocols.

Treatment & Management

Functional genomics informs several aspects of cell therapy management: donor selection, conditioning regimens, cell product engineering, and post-transplant monitoring. By identifying donors with favorable immune signatures or minimal alloreactive potential, clinicians can personalize treatment and reduce risks. Genomic insights also enable the optimization of cell expansion, activation, and gene editing techniques, aligning therapeutic potency with patient-specific needs. Ongoing monitoring of recipient immune responses using functional genomic biomarkers supports early detection of complications and timely intervention.

Recent Advances / Emerging Therapies

Recent advances include the integration of multi-omics platforms to generate comprehensive donor and recipient profiles. Artificial intelligence (AI) and machine learning algorithms are being applied to large-scale genomic datasets to predict compatibility and outcomes. CRISPR-mediated genome editing is enabling precise modification of donor cells to enhance persistence, reduce immunogenicity, or confer resistance to disease recurrence. Emerging cell therapies—such as universal CAR-T cells, induced pluripotent stem cell (iPSC)-derived products, and engineered regulatory T cells—are leveraging functional genomics for improved safety and efficacy.

Guideline Recommendations

Consensus guidelines from major organizations, including the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Transplantation and Cellular Therapy (ASTCT), increasingly endorse the use of extended genomic and functional assessments in donor selection and cell product characterization. Recommendations emphasize integration of functional genomics with traditional HLA typing, risk stratification, and therapeutic monitoring, with the goal of achieving individualized cell therapy that maximizes benefit and minimizes harm.

Conclusion

Functional genomics represents a paradigm shift in cell-therapy matching, offering unprecedented resolution in understanding and optimizing donor-recipient compatibility. By bridging the gap between genetic information and functional cellular phenotypes, clinicians can improve patient outcomes, reduce complications, and expand the therapeutic potential of cell-based interventions. Ongoing research, technological innovation, and guideline development will further refine these approaches, cementing functional genomics as an integral component of precision medicine in regenerative therapies.